FDAClass III · Drug · Recalled June 10, 2026

Lidocaine HCl Injection recall — Eugia US LLC

Hazard: Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Class III: not likely to cause adverse health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID: D-0552-2026
Brand: Eugia US
Classification: Class III
Units affected: 168,300 vials
Recall status: Ongoing
Initiated: Voluntary: Firm initiated

Description

Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520. NDC: 55150-164-02

Affected products

Lidocaine HCl Injection

Companies & origin

Recalling firm location: East Windsor, NJ, United States
Firm address: 279 Princeton Hightstown Rd, 08520-1401

Identifying details (verbatim from the notice)

Product codes / lots: Lot, expiry: Lot 3LC26029A, exp Feb-2029; Lot 3LC26031A, exp Mar-2029
Distribution: US Nationwide.
Firm notified the public via: Letter
FDA event ID: 99024
Recall initiated: May 18, 2026
FDA classified: May 29, 2026
FDA report date: June 10, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 24, 2026 at 12:00 AM UTC.

Report a data error on this page